keyword
MENU ▼
Read by QxMD icon Read
search

radium

keyword
https://www.readbyqxmd.com/read/29234845/eanm-guideline-for-radionuclide-therapy-with-radium-223-of-metastatic-castration-resistant-prostate-cancer
#1
Thorsten D Poeppel, Daria Handkiewicz-Junak, Michael Andreeff, Alexander Becherer, Andreas Bockisch, Eva Fricke, Lilli Geworski, Alexander Heinzel, Bernd J Krause, Thomas Krause, Markus Mitterhauser, Wilfried Sonnenschein, Lisa Bodei, Roberto C Delgado-Bolton, Michael Gabriel
Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is the first targeted alpha therapy in this indication providing a new treatment option, with evidence of a significant survival benefit, both in overall survival and in the time to the first symptomatic skeletal-related event. The skeleton is the most common metastatic site in patients with advanced prostate cancer...
December 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29232987/radium-223-international-early-access-program-results-from-the-spanish-subset
#2
Joan Carles, Mª José Méndez, Álvaro Pinto, Mª Isabel Sáez, José A Arranz, Pablo Maroto, Pilar López-Criado, Begoña Mellado, Jesús García Donas, Susana Hernando, Luís León, Aránzazu González Del Alba, Núria Laínez, Emilio Esteban, Gaspar Reynés, José L Pérez-Gracia, Josep R Germà, Marta López-Brea, Begoña Pérez-Valderrama, Cristina Moretones, Daniel Castellano
AIM: To report results from the Spanish subset included in the radium-223 international early access program (iEAP). PATIENTS & METHODS: Ninety patients with castration-resistant prostate cancer and bone metastases received radium-223 55 kBq/kg every 4 weeks for six cycles. RESULTS: The median time to disease progression was 8 months and to prostate-specific antigen progression was 4 months. The percentage of patients with ≥50% confirmed declines in prostate-specific antigen was 9%...
December 13, 2017: Future Oncology
https://www.readbyqxmd.com/read/29227877/spatial-variations-of-226ra-228ra-134cs-and-137cs-concentrations-in-western-and-southern-waters-off-the-korean-peninsula-in-july-2014
#3
M Inoue, Y Shirotani, S Nagao, T Aramaki, Y I Kim, K Hayakawa
We examined the spatial distributions of 226Ra, 228Ra, 134Cs, and 137Cs concentrations (activities) in seawater off the western and southern Korean Peninsula in July 2014. Radium-228 (and 226Ra) concentrations in water samples varied widely from 5 to 14 mBq/L (2-4 mBq/L), showing a negative correlation with salinity, particularly at the surface off the western Korean Peninsula. This indicates that the seawaters in this area are fundamentally comprised of 228Ra-poor and high-saline Kuroshio Current water and 228Ra-rich and low-saline water (e...
December 8, 2017: Journal of Environmental Radioactivity
https://www.readbyqxmd.com/read/29211691/long-term-monitoring-of-water-treatment-technology-designed-for-radium-removal-removal-efficiencies-and-norm-formation
#4
Liie Hill, Siiri Suursoo, Madis Kiisk, Alar Jantsikene, Nele Nilb, Rein Munter, Enn Realo, Rein Koch, Kaisa Putk, Maria Leier, Taavi Vaasma, Kadri Isakar
A drinking water treatment plant in Viimsi, Estonia, was monitored over three years for iron, manganese, radium-226, radium-228, as well as their daughter nuclides, in order to determine the efficiency of the treatment process, gain an insight into the removal mechanisms and interactions between radium, iron, and manganese, and assess the overall longevity and performance of the technology along with the possible build-up of NORM in the treatment process. During the study, samples were collected from raw water, first and second stage filtrate, consumer water, backwash water and filter materials...
December 6, 2017: Journal of Radiological Protection: Official Journal of the Society for Radiological Protection
https://www.readbyqxmd.com/read/29196208/eradicate-a-prospective-evaluation-combining-radium-223-dichloride-and-abiraterone-acetate-plus-prednisone-in-patients-with-castration-resistant-prostate-cancer
#5
Neal D Shore, Ronald F Tutrone, Neil F Mariados, Luke T Nordquist, Bryan A Mehlhaff, Karyn J Steere, Stacey S Harrelson
BACKGROUND: Multiple castration-resistant prostate cancer (CRPC) therapies are approved by the United States Food and Drug Administration. Radium-223 dichloride (Ra-223) with abiraterone acetate plus prednisone have different mechanisms of action and distinct off-target side-effect profiles. We prospectively investigated their combined safety, tolerability, and patient-reported outcome measures. PATIENTS AND METHODS: eRADicAte, an investigator-initiated, phase II trial, studied 31 patients with metastatic CRPC, from 5 United States uro-oncology research sites...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29189490/excretion-and-whole-body-retention-of-radium-223-dichloride-administered-for-the-treatment-of-bone-metastases-from-castration-resistant-prostate-cancer
#6
Brenda E Pratt, Cecilia Hindorf, Sarah J Chittenden, Christopher C Parker, Glenn D Flux
OBJECTIVE: The aim of the study was to determine the fraction of administered activity that was excreted and retained by a small cohort of patients who each received treatment with radium-223 dichloride (Ra). Ra is an α-emitting radionuclide that has been approved for use in the treatment of bone metastases that are secondary to castration resistant prostate cancer. PATIENTS AND METHODS: Six patients received two weight-based administrations of Ra 6 weeks apart...
November 17, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29187768/barium-and-radium-complexation-with-ethylenediaminetetraacetic-acid-in-aqueous-alkaline-sodium-chloride-media
#7
Artem V Matyskin, Niklas L Hansson, Paul L Brown, Christian Ekberg
The speciation of Ra2+ and Ba2+ with EDTA was investigated at 25 °C in aqueous alkaline NaCl media as a function of ionic strength (0.2-2.5 mol·L-1) in two pH regions where the EDTA4- and HEDTA3- species dominate. The stability constants for the formation of the [BaEDTA]2- and [RaEDTA]2- complexes were determined using an ion exchange method. Barium-133 and radium-226 were used as radiotracers and their concentrations in the aqueous phase were measured using liquid scintillation counting and gamma spectrometry, respectively...
2017: Journal of Solution Chemistry
https://www.readbyqxmd.com/read/29183960/radium-223-safety-efficacy-and-concurrent-use-with-abiraterone-or-enzalutamide-first-u-s-experience-from-an-expanded-access-program
#8
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, Daniel C Fernandez, Fabio Almeida, Andrei Iagaru, Alan Brown, Matthew R Smith, Manish Agrawal, Adam P Dicker, Jorge A Garcia, Jose Lutzky, Yu-Ning Wong, Oana Petrenciuc, Jeremy Gratt, Neal D Shore, Michael J Morris
BACKGROUND: In the phase III ALSYMPCA trial, metastatic castration-resistant prostate cancer (mCRPC) patients had few prior life-prolonging therapies. Following ALSYMPCA, which demonstrated radium-223 survival benefit, and before radium-223 U.S. commercial availability, an expanded access program (EAP) providing early-access radium-223 allowed life-prolonging therapies in current use. SUBJECTS, MATERIALS, AND METHODS: This phase II, open-label, single-arm, multicenter U...
November 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29181271/radium-223-in-metastatic-hormone-sensitive-high-grade-prostate-cancer-initial-experience
#9
García-Pérez Francisco Osvaldo, Medina-Ornelas Sevastián Salvador, Santana-Ríos Zael, Sobrevilla-Moreno Nora
Our study evaluates the feasibility of compassionate exemption of Radium-223 (223Ra) treatment in metastatic hormone-sensitive high-grade prostate cancer (mHSHGPC) patients with concomitant androgen deprivation-therapy (ADT). Seven patients with mHSHGPC, were treated with six cycles of 223Ra plus ADT. All patients had undergone to 18F-NaF-PET/CT. A qualitative analyses of the 18F-NaF-PET/CT was performed in conjunction with Alkaline Phosphatase (ALP), Lactate-dehydrogenase (LDH) and Prostatic-Specific Antigen (PSA) values...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29174502/lymph-node-response-in-a-patient-with-metastatic-castration-resistant-prostate-cancer-treated-with-radium-223
#10
Darren M C Poon, Kenneth C W Wong
No abstract text is available yet for this article.
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29158857/the-brca2-variant-c-68-7-t-a-is-associated-with-breast-cancer
#11
Pål Møller, Eivind Hovig
Background: BRCA2 c.68-7T>A has been demonstrated to cause aberrant splicing and is possibly pathogenic. The population prevalence of the variant is 0.2%, which higher than usual for pathogenic BRCA2 variants. The pathogenicity of the variant is discussed. Methods: The outpatient genetic clinic at The Norwegian Radium Hospital, part of Oslo University Hospital, has invited breast cancer kindreds for genetic examinations and prospective follow-up of high risk patients since 1988...
2017: Hereditary Cancer in Clinical Practice
https://www.readbyqxmd.com/read/29139032/radium-biophysics-and-radiobiology-tracing-the-history-of-radiobiology-in-twentieth-century-china
#12
Christine Yi Lai Luk
Radiobiology assesses the biological hazards of exposure to radioactive substances and nuclear radiation. This article explores the history of radiobiology in twentieth-century China by examining the overlapping of radium research and biophysics, from roughly the 1920s Nationalist period to the 1960s Communist period; from the foreign purchase of radium by the Rockefeller Foundation's China Medical Board during the Republican era, to the institutional establishment of radiobiology as a subset of biophysics in the People's Republic...
November 2, 2017: History and Philosophy of the Life Sciences
https://www.readbyqxmd.com/read/29137877/immune-analysis-of-radium-223-in-patients-with-metastatic-prostate-cancer
#13
Joseph W Kim, Min Sun Shin, Youna Kang, Insoo Kang, Daniel P Petrylak
BACKGROUND: Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown. PATIENTS AND METHODS: Fifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Patients received a course of Ra223 50 kBq/kg...
October 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29134562/seom-clinical-guidelines-for-the-treatment-of-metastatic-prostate-cancer-2017
#14
J Cassinello, J Á Arranz, J M Piulats, A Sánchez, B Pérez-Valderrama, B Mellado, M Á Climent, D Olmos, J Carles, M Lázaro
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29123148/radiological-investigation-of-high-background-radiation-areas
#15
Fawzia Mubarak, M Fayez-Hassan, N A Mansour, Talaat Salah Ahmed, Abdallah Ali
In this paper, we used the Hyper-Pure Germanium (HPGe) detector to measure 30 samples which are collected from north of Nile Delta near Rosetta beach in Egypt. The activity of primordial radionuclides, such as (238)U, (235)U, (232)Th, and (40)K was estimated. Concentrations ranged between 36.5-177.4, 50-397.5 and 56.1-168.9 Bq.kg(-1) for (238)U, (232)Th and (40)K respectively. Activity concentration of (235)U and the variation in uranium isotopic ratio (235)U/(238)U was calculated. External hazard indices (Hex) (or radium equivalent activity Raeq), activity concentration indices (I), alpha index (Iα), absorbed outdoor gamma dose rate (Dout), effective outdoor gamma dose rate (Eout) and Excess Lifetime Cancer Risk (ELCR) due to different samples are estimated...
November 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29101113/treatment-of-advanced-prostate-cancer-a-review-of-current-therapies-and-future-promise
#16
Semini Sumanasuriya, Johann De Bono
Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCRPC), the disease remains incurable, although men suffering from this disease are living considerably longer. In this review, we discuss the current treatment options available for this disease, such as taxane-based chemotherapy, the novel hormone therapies abiraterone and enzalutamide, and treatments such as radium-223 and sipuleucel-T. We also highlight the need for ongoing research in this field, because, despite numerous recent advances, the prognosis for mCRPC remains poor...
November 3, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29100167/early-identification-and-intervention-matters-a-comprehensive-review-of-current-evidence-and-recommendations-for-the-monitoring-of-bone-health-in-patients-with-cancer
#17
REVIEW
Thomas Brodowicz, Peyman Hadji, Daniela Niepel, Ingo Diel
Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability...
October 18, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29098984/long-term-monitoring-of-a-water-treatment-technology-designed-for-radium-removal-removal-efficiencies-and-norm-formation
#18
Liie Lumiste Hill, Siiri Suursoo, Madis Kiisk, Alar Jantsikene, Nele Nilb, Rein Munter, Enn Realo, Rein Koch, Kaisa Putk, Maria Leier, Taavi Vaasma, Kadri Isakar
A drinking water treatment plant in Viimsi, Estonia was monitored over three years for iron, manganese, radium-226, radium-228, and their daughter nuclides in order to determine the efficiency of the treatment process, get an insight of the removal mechanisms and interactions between radium, iron, and manganese, and assess the overall longevity and performance of the technology and possible build-up of NORM from the treatment process. During the study, samples were collected from raw water, first and second stage filtrate, consumer water, backwash water, and filter materials...
November 3, 2017: Journal of Radiological Protection: Official Journal of the Society for Radiological Protection
https://www.readbyqxmd.com/read/29098556/selection-and-monitoring-of-patients-with-metastatic-castration-resistant-prostate-cancer-for-treatment-with-radium-223
#19
REVIEW
A Rodriguez-Vida, M D Torregrosa, Á Pinto, M Á Climent, D Olmos, J Carles
Despite the improvement provided by androgenic suppression in the treatment of prostate cancer, most of tumors develop resistance to castration. However, new therapies have demonstrated an increase in patient survival such as radium-223 (Ra-223), an alpha emitter and calcium mimetic with the capability of targeting osteoblastic metastatic lesions. According to results of the ALSYMPCA phase III trial, Ra-223 has demonstrated its activity by improving symptoms and survival of patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases, and no known visceral metastatic disease, without interfering with subsequent treatments...
November 2, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29096952/lingering-radioactivity-at-the-bikini-and-enewetak-atolls
#20
Ken O Buesseler, Matthew A Charette, Steven M Pike, Paul B Henderson, Lauren E Kipp
We made an assessment of the levels of radionuclides in the ocean waters, seafloor and groundwater at Bikini and Enewetak Atolls where the US conducted nuclear weapons tests in the 1940's and 50's. This included the first estimates of submarine groundwater discharge (SGD) derived from radium isotopes that can be used here to calculate radionuclide fluxes in to the lagoon waters. While there is significant variability between sites and sample types, levels of plutonium ((239,240)Pu) remain several orders of magnitude higher in lagoon seawater and sediments than what is found in rest of the world's oceans...
October 24, 2017: Science of the Total Environment
keyword
keyword
30748
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"